

LAW OFFICES

**SHOOK, HARDY & BACON**

THE FIRM IS AN  
S.U.T. TELE. 4281 848 830  
A PARTNERSHIP INCLUDING PROFESSIONAL  
CORPORATIONS

ONE KANSAS CITY PLACE  
1200 MAIN STREET  
KANSAS CITY, MISSOURI 64105  
(816) 474-8550

OTHER OFFICES  
40 CORPORATE WOODS  
OVERLAND PARK, KANSAS  
18 BUCKINGHAM GATE  
LONDON, ENGLAND

December 10, 1991

Wayne W. Juchatz, Esq.  
Josiah S. Murray, III, Esq.  
Ernest Pepples, Esq.  
Paul A. Randour, Esq.  
Arthur J. Stevens, Esq.  
Charles R. Wall, Esq.



LAW DEPARTMENT

Re: Dr. Rodger L. Bick

Gentlemen:

Dr. Rodger Bick is requesting funding for a study to assess platelet function in patients with coronary artery disease occurring before the age of 50. We recommend that this project be approved in the amount of \$139,600.75 to be funded directly by the companies. A copy of the proposal is enclosed.

Dr. Bick's continuing research on lung cancer rates in Kern County, California, has been supported by the industry for more than ten years. In recent years, Dr. Bick has also become interested in the study of blood protein defects which apparently account for many instances of premature coronary artery disease and coronary artery bypass graft failure. A pilot study involving patients with heart disease was funded by Philip Morris last year that resulted in presentations at several international meetings and publications. The proposed study focusing on platelet function is important because platelet aggregation has been mentioned in recent literature as a possible mechanism by which smoking may cause heart disease.

Dr. Bick is a practicing hematologist-oncologist in Bakersfield, California. He has published numerous scientific articles, book chapters, and textbooks (a copy of his C.V. is attached). Dr. Bick's Regional Cancer and Blood Disease Center of Kern has recently become a part of UCLA Medical School, and Dr. Bick has been made a full professor. Dr. Bick has been a valuable consultant in smoking and health litigation for many years.

We recommend that funding for Dr. Bick's research be provided on a market share basis. Based on recent Maxwell figures


LG 2001167

(12 months ending June 1991), the requested funding per company is as follows:

Philip Morris (43.2%)	\$60,307.52
Reynolds (28.1%)	39,227.81
Brown & Williamson (10.7%)	14,937.28
Lorillard (7.6%)	10,609.66
American (7.0%)	9,772.05
Liggett (3.4%)	4,746.43

Your early response would be appreciated.

Sincerely,

  
Patrick M. Sirridge

PMS:as

Enclosures

cc: Thomas E. Bezanson, Esq. (w/encl.)  
Francis K. Decker, Esq. (w/encl.)  
Daniel W. Donahue, Esq. (w/encl.)  
Michael A. Nims, Esq. (w/encl.)

10482773

LG 2001168